ADAG:NSD-Adagene Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 20.68

Change

+0.80 (+4.02)%

Market Cap

USD 0.77B

Volume

0.07M

Avg Analyst Target

USD 35.14 (+69.93%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+2.37 (+0.74%)

USD128.93B 215.22 167.82
BNTX BioNTech SE

+21.37 (+8.23%)

USD62.70B 47.24 36.74
REGN Regeneron Pharmaceuticals, Inc

+3.16 (+0.54%)

USD62.19B 16.62 13.12
VRTX Vertex Pharmaceuticals Incorpo..

-0.25 (-0.13%)

USD50.81B 18.71 13.00
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 41.97
BGNE BeiGene, Ltd

+15.11 (+4.93%)

USD29.15B N/A N/A
GMAB Genmab A/S

+0.21 (+0.48%)

USD28.86B 32.84 3.64
SGEN Seagen Inc

-0.27 (-0.19%)

USD26.06B 40.07 36.19
RPRX Royalty Pharma plc

-0.95 (-2.30%)

USD25.34B 34.40 14.43
ALNY Alnylam Pharmaceuticals, Inc

+1.72 (+0.96%)

USD21.17B N/A N/A

ETFs Containing ADAG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.77B 68% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.03 17% F 15% F
Price / Cash Flow Ratio -27.00 82% B- 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.26% 53% F 29% F
Return on Invested Capital 28.22% 92% A- 94% A
Return on Assets -28.37% 39% F 12% F
Debt to Equity Ratio -3.32% 90% A- 93% A
Technical Ratios  
Short Ratio 1.71 69% D+ 61% D-
Short Percent 0.60% 94% A 84% B
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector